Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry
| Autor: | Manfred Gerlach, M Romanos, Su-Yin Dang, Karin Egberts, C. Mehler-Wex, R Taurines, Paul L. Plener |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Adolescent Routine practice Off-label use Pharmacovigilance 03 medical and health sciences Patient safety 0302 clinical medicine Child and adolescent psychiatry Humans Medicine 0501 psychology and cognitive sciences Pharmacology (medical) Dosing Child Psychiatry Psychotropic Drugs Dose-Response Relationship Drug medicine.diagnostic_test business.industry 05 social sciences Age Factors Off-Label Use General Medicine Psychotropic drug use Therapeutic drug monitoring Drug Monitoring business 030217 neurology & neurosurgery 050104 developmental & child psychology |
| Zdroj: | Expert Opinion on Drug Safety. 15:1477-1482 |
| ISSN: | 1744-764X 1474-0338 |
| DOI: | 10.1080/14740338.2016.1225721 |
| Popis: | Off-label or unlicensed use of psychotropic drugs is common rather than the exception in child and adolescent psychiatry. This use exposes patients to an unknown additional risk of ineffective or even harmful treatment. In addition, treatment with psychotropic drugs during a period of life when the patient undergoes marked developmental hormonal and neurobiological changes often requires different dosing regimes in later life and may result in adverse drug reactions, which are either not seen in adults at all or not in the same frequency. Areas covered: Given these critical safety issues, efficient pharmacovigilance methods as part of routine practice are essential for the improvement of patient care. The purpose of this article is to introduce methods to increase the safety of psychotropic drug use in youngsters. In particular, therapeutic drug monitoring (TDM) as a routine measure of proactive pharmacovigilance is discussed. Expert opinion: Given the special features of psychopharmacological therapy in children and adolescents in day-to-day clinical practise, proactive surveillance by using a close standardized 'patient monitoring' and long-term follow-up with TDM is very important. This approach could minimize the risk of exposing paediatric patients to ineffective treatments of uncertain or unknown risks. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|